STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Medpace Holdings, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) disclosed an insider sale by an executive officer. Exec. VP, Operations Susan E. Burwig sold 18,000 shares of common stock on 11/11/2025 at a price of $605 per share (Transaction Code S). Following the sale, she beneficially owns 47,500 shares, held directly.

The filing notes the trade was executed via a limit order during an open window period.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BURWIG SUSAN E

(Last) (First) (Middle)
C/O MEDPACE HOLDINGS, INC.
5375 MEDPACE WAY

(Street)
CINCINNATI OH 45227

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Exec. VP, Operations
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/11/2025 S(1) 18,000 D $605 47,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
Remarks:
/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig 11/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MEDP report on Form 4?

Exec. VP, Operations Susan E. Burwig sold 18,000 MEDP shares on 11/11/2025 (Code S).

What was the sale price per share in the MEDP transaction?

The reported price was $605 per share.

How many MEDP shares does the reporting person own after the sale?

She beneficially owns 47,500 shares following the transaction.

What is the ownership form of the remaining MEDP shares?

The shares are held directly (D).

How was the MEDP trade executed?

The filing states it was made via a limit order during an open window period.

Who is the reporting person’s role at MEDP?

She is Exec. VP, Operations.
Medpace Holdings

NASDAQ:MEDP

MEDP Rankings

MEDP Latest News

MEDP Latest SEC Filings

MEDP Stock Data

16.66B
22.39M
20.7%
96.78%
8.02%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
CINCINNATI